Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4824 - Medical Costs and Health Care Resource Use (HCRU) in Elderly US Patients (pts) With Newly Diagnosed Metastatic or Surgically Unresectable Urothelial Carcinoma (mUC) Using Surveillance, Epidemiology, and End Results (SEER) Medicare Data

Date

10 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Bioethical Principles and GCP;  Geriatric Oncology;  Urothelial Cancers

Presenters

Abdalla Aly

Citation

Annals of Oncology (2017) 28 (suppl_5): v395-v402. 10.1093/annonc/mdx375

Authors

A. Aly1, C. Johnson1, S. Yang2, S. Rao3, M. Botteman1, A. Hussain4

Author affiliations

  • 1 Real-world Evidence And Data Analytics, Pharmerit International, Inc, 20814 - Bethesda/US
  • 2 Heor, Bristol-Myers Squibb, Princeton/US
  • 3 Immunooncology, Us Heor, Bristol-Myers Squibb, Princeton/US
  • 4 Medicine, University of Maryland Medical Center, Baltimore/US
More

Resources

Abstract 4824

Background

Most elderly mUC pts receive platinum-based therapy as first line of treatment (LOT) but invariably progress, requiring additional LOT and HCRU. This analysis estimated medical costs and HCRU associated with each LOT in US elderly pts.

Methods

Pts ≥66 years of age newly diagnosed with mUC (urothelial transitional cell carcinoma) between 2004 and 2011 were identified from the SEER-Medicare database. Pts were followed from diagnosis to death, Medicare disenrollment, HMO enrollment, or till 31 December 2013 to characterize treatments by LOT (first [1L], second [2L], and third + [3L+] LOT). The per-pt HCRU was examined. Cumulative mean costs (overall and by type of LOT) were reported.

Results

Among 1,873 eligible mUC pts (median age, 77 years; male, 63%; Charlson comorbidity index ≥2, 29%; median follow-up, 7.5 months), 1,035 (55%) pts did not receive any chemotherapy. Among the 838 chemotherapy-treated pts, 510 (61%), 204 (24%), and 124 (15%) received 1L, 2L, and 3L+ LOT, respectively. Compared with 2L, 3L+ pts had significantly higher mean (standard deviation) per-pt hospital admissions (4.1 [2.9] vs 4.8 [3.3]), computed tomography (CT) scans (7.4 [4.4] vs 9.9 [5.8]), positron emission tomography–CT scans (1.0 [1.5] vs 2.0 [2.9]), and bone scans (1.1 [1.1] vs 1.8 [2.3]). Pts who received 3L+ LOT had significantly higher cumulative mean costs than 2L pts, mostly attributed to physician and outpatient services where chemotherapy is administered (Table).Table:

1131P Cumulative per-patient costs from 3 months before diagnosis to end of follow-up (% total)

Cost categoryAll patients (N = 1,873)No chemotherapy (N = 1,035)1L only (N = 510)2L only (N = 204)3L + (N = 124)P-value (3L+ vs 2L)
Median follow-up time, months7.53.811.816.126.5
Mean costs (%), $US82,912 (100)57,208 (100)99,422 (100)123,262 (100)162,549 (100)

Conclusions

For pts with mUC, cumulative mean costs increased with additional LOT, although further analysis of cumulative costs over the treatment duration of each LOT is warranted. As the treatment landscape evolves to include immunotherapy, this analysis provides a benchmark for the relative costs associated with mUC treatment across different traditional LOT in the United States.

Clinical trial identification

N/A

Legal entity responsible for the study

Bristol-Myers Squibb

Funding

Bristol-Myers Squibb

Disclosure

A. Aly: Reports grants from Bristol-Myers Squibb, during the conduct of the study; grants from Bristol-Myers Squibb, Celldex, Celgene, Daiichi Sankyo, Pharmacyclics, and Amgen, outside the submitted work. C. Johnson: Reports grants from Bristol-Myers Squibb, during the conduct of the study. S. Yang, S. Rao: Reports personal fees from Bristol-Myers Squibb, during the conduct of the study; personal fees from Bristol-Myers Squibb, outside the submitted work. M. Botteman: Reports grants from Bristol-Myers Squib, during the conduct of the study; grants from Bristol-Myers Squib, Celgene, Celldex, Shire, outside the submitted work; and is an employee and owner of Pharmerit International. A. Hussain: Served as a consultant for Bristol-Myers Squibb.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.